[G25-03] Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – Addendum to Project A24-85
Last updated 15.04.2025
Project no.:
G25-03
Commission:
Commission awarded on 07.01.2025 by the Federal Joint Committee (GBA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Head and nerves
Note:
If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.
The current version 1.1 of the addendum replaces version 1.0 published on Feb 20, 2025.
DOI:
https://doi.org/10.60584/G25-03_V1.1
| Project no. | Title | Status |
|---|---|---|
| A24-85 | Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-02-20 A G-BA decision was published.